HOPA 2018 | Drugs with low response rates – should they always be offered to patients?

From the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference held in Denver, CO, Jacob Kettle, PharmD, BCOP, of the University of Missouri Health Care, Columbia, MO, gives his insight on the factors that need to be considered when administering drugs with low response rates, as applying a treatment like this may worsen outcomes at a time when palliative or end-of-life care would be more beneficial. Dr Kettle also discusses how the application of testing for PD-L1 is not as straightforward as that for other cancer biomarkers, such as HER2, BRAF and ALK.